Martin I. Freed - Concepedia

Author

Martin I. Freed

GlaxoSmithKline (United States)

Also Known As

M FREED, M I Freed, M. I. Freed, Martin Freed, Martin I Freed, Martin I. Freed, N. Katsilambros, Y. Imai

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)New Frontier University of Pennsylvania Health System Penn Presbyterian Medical Center The University of Texas Health Science Center at San Antonio

About

Martin I. Freed is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.2K
2	Health Sciences	3	3	291
3	Biochemistry	2	2	40
4	Natural Sciences	1	1	26
5	Cell Biology	1	1	26

Martin I. Freed

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus Steven M. Haffner, Andrew S. Greenberg, Wayde M. Weston, Circulation	2002	877
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes Harold E. Lebovitz, Jo Dole, Rita Patwardhan, The Journal of Clinical Endocrinology & Metabolism	2001	503
A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes Philip Raskin, Marc Rendell, Matthew C. Riddle, Diabetes Care	2001	343
Improving Metabolic Control Leads to Better Working Memory in Adults With Type 2 Diabetes Christopher M. Ryan, Martin I. Freed, Julie A. Rood, Diabetes Care	2006	287
A Diabetes Outcome Progression Trial (ADOPT) Giancarlo Viberti, Steven E. Kahn, Douglas A. Greene, Diabetes Care	2002	269
A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes Martin St. John Sutton, Marc Rendell, Paresh Dandona, Diabetes Care	2002	254
Rosiglitazone reduces urinary albumin excretion in type II diabetes George L. Bakris, Giancarlo Viberti, Wayde M. Weston, Journal of Human Hypertension Metabolic SyndromeDiabetes ManagementUrologyMedicineDiabetes	2003	240
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus Martin I. Freed, Robert E. Ratner, Santica M. Marcovina, The American Journal of Cardiology Metabolic SyndromeCardiovascular DiseaseMedicineDiabetesPhysiology	2002	239
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism Andrew Wang, Terry L. Holcslaw, Thomas M. Bashore, Kidney International Endothelin Receptor AntagonismMedicinePhysiologyEndothelial DysfunctionVascular Biology	2000	232
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans Erica N Evans, Richland Tester, Sharon Aslanian, Journal of Pharmacology and Experimental Therapeutics	2013	219

Page 1